Improving quality of life in DME patients

Article

Intravitreal ranibizumab (IVR) has been found to improve vision related quality of life in diabetic macular oedema (DME) patients, notes a study recently published in the Journal of Diabetes and Its Complications.

Intravitreal ranibizumab  (IVR) has been found to improve vision related quality of life in diabetic macular oedema (DME) patients, notes a study recently published in the Journal of Diabetes and Its Complications.

The prospective study, performed by Dr Elif Turkoglu et al. of Akdeniz University, Department of Ophthalmology, Antalya, Turkey, compared the changes in vision related quality of life in DME patients either undergoing treatment with IVR or focal/grid laser. Seventy patients were included in the study group who all had clinically significant macular oedema (CSME). Patients were randomly assigned into two groups, either receiving IVR or laser treatment, and treatments were repeated when necessary.

Both demographic and clinical findings were similar for both groups before treatment. However, the improvements in distance and near visual acuities and the reduction in central retinal thickness (CRT) were greater in the IVR group compared with the laser group.

For vision related quality of life, both groups saw improvement from baseline to 6 months but the improvement in the overall composite score for the IVR group was 6.3 points and only 3 points for the laser group.

 

As a result of their findings, the researchers report that IVR is a useful treatment for improvement of visual acuity, CRT and vision related quality of life and offers a better outcome for patients over laser treatment. Further, they claim that these patient-reported outcomes could have an important role in DME treatment choice.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.